ArticleBMC psychiatry2025
Alteration of microRNA expression in lymphocytes in patients with first-episode schizophrenia.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Identification of a miRNA signature for schizophrenia in plasma-derived extracellular vesicles.bioRxiv : the preprint server for biology · 2026Article
- Plasma microRNA signatures in drug-naïve Romanian adolescents with first-episode psychosis.Frontiers in psychiatry · 2026Article
- Brain miR-137 governs growth and development via GH/IGF-1 signaling.BMC biology · 2025Article
- Effect of Electroconvulsive Therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and Soluble IL-2 Receptor in Treatment-Resistant Schizophrenia (TRS) Patients-A Preliminary Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe development of schizophrenia is related to a combination of genetic and epigenomic factors. MicroRNAs (miRNAs) play a crucial role in epigenetic processes and are relevant to the onset and progression of schizophrenia. They can regulate target genes during the growth and development of neurons and can be affected by genetic and environmental factors associated with schizophrenia. Although prior studies have found abnormal miRNA expression in schizophrenia, few studies have examined the miRNA level in first-episode schizophrenia (FES). The present study aimed to examine the expression of lymphocyte microRNA (miR-107, miR-181a, miR-181b, miR-223, miR-219, miR-137, miR-125b) in patients with first-episode schizophrenia who had never been treated.
methodWe investigated the expression of miRNAs using the real-time polymerase chain reaction (RT-PCR) technology. The severity of clinical symptoms was assessed using Positive and Negative Syndrome Scale (PANSS). The prognostic value of biomarkers was analyzed using receiver operating characteristic (ROC) curves, and the predictive value of these biomarkers was also compared. Logistic regression analysis was used to assess the relative risk related to microRNA alteration in schizophrenia. Logistic regression analyses were then performed to identify the most significant and sensitive miRNA biomarkers.
resultsCompared with the control group, the patient group exhibited significantly higher levels of expression for six miRNAs (miR-181a, miR-137, miR-223, miR-107, miR-181b, and miR-125b) (P < 0.05). The ROCs indicated that miR-223 exhibited the highest diagnostic value, with an area under the curve being 0.916.
conclusionsThe present study provided some insights into the alteration of miRNA expression, which might improve our understanding of the complex global changes in gene expression in the pathophysiology of schizophrenia. This study identified six miRNAs (miR-223, miR-181a, miR-181b, miR-125b, miR-219, and miR-107) that might facilitate the diagnosis of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.